The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival
The full LUNAR data will be presented at a future medical congress
Novocure (NASDAQ:NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a pivotal, open-label, randomized study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on or after treatment with platinum-based therapy.
